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Abstract
Background: Direct supplementation or food fortification with iron are two public health initiatives intended to
reduce the prevalence of iron deficiency (ID) and iron deficiency anaemia (IDA) in 4–24-month-old infants. In most
high-income countries where IDA prevalence is < 15%, the recommended daily intake levels of iron from
supplements and/or consumption of fortified food products are at odds with World Health Organisation (WHO)
guidelines that recommend shorter-term (3 months/year) supplementation only in populations with IDA prevalence
> 40%. Emerging concerns about delayed neurological effects of early-life iron overexposure have raised questions
as to whether recommended guidelines in high-income countries are unnecessarily excessive. This systematic
review will gather evidence from supplementation/fortification trials, comparing health outcomes in studies where
iron-replete children did or did not receive additional dietary iron; and determine if replete children at study outset
were not receiving additional iron show changes in haematological indices of ID/IDA over the trial duration.
Methods: We will perform a systematic review of the literature, including all studies of iron supplementation and/or
fortification, including study arms with confirmed iron-replete infants at the commencement of the trial. This includes
both dietary iron intervention or placebo/average dietary intakes. One reviewer will conduct searches in electronic
databases of published and ongoing trials (Medline, Web of Science, Scopus, CENTRAL, EBSCO [e.g. CINAHL Complete,
Food Science and Technology Abstracts], Embase, ClinicalTrials.gov, ClinicalTrialsRegister.eu and who.it/trialsearch),
digital theses and dissertations (WorldCat, Networked Digital Library of Theses and Dissertations, DART-Europe E-theses
Portal, Australasian Digital Theses Program, Theses Canada Portal and ProQuest). For eligible studies, one reviewer will
use a data extraction form, and a second reviewing entered data for accuracy. Both reviewers will independently
perform quality assessments before qualitative and, if appropriate, quantitative synthesis as a meta-analysis. We will
resolve any discrepancies through discussion or consult a third author to resolve discrepancies. The Preferred Reporting
Items for Systematic Reviews and Meta-Analyses statement will be used as the basis for reporting.
(Continued on next page)
© The Author(s). 2019 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0
International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to
the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver
(http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
* Correspondence: dominic.hare@florey.edu.au
1The Peter Doherty Institute for Infection and Immunity at The University of
Melbourne, 792 Elizabeth Street, Melbourne, VIC 3000, Australia
2Department of Medicine at the Royal Melbourne Hospital and The
University of Melbourne, 300 Grattan Street, Parkville, VIC 3052, Australia
Full list of author information is available at the end of the article
Hare et al. Systematic Reviews           (2019) 8:253 
https://doi.org/10.1186/s13643-019-1185-3
(Continued from previous page)
Discussion: Recommended iron supplementation and food fortification practices in high-income countries have been
criticised for being both excessive and based on outdated or underpowered studies. This systematic review will build a
case for revisiting iron intake guidelines for infants through the design of new trials where health effects of additional
iron intake in iron-replete infants are the primary outcome.
Systematic review registration: PROSPERO CRD42018093744.




Adequate dietary iron intake during early life is crucial
for several developmental processes, particularly in the
brain. Exclusively breastfed term infants have access to
sufficient levels of iron for the first 4–6 months of life,
during which 20–40%, (~ 50–100 mg) of total body iron
at birth is recycled from excess haemoglobin (Hb) and
stored for later use [1], with an additional ~ 0.15 mg
absorbed from breastmilk containing around 0.5 mg/L
of iron per day [2]. Foetal iron demand is highest dur-
ing the third trimester [3]; thus pre-term and low birth-
weight infants are generally considered at higher risk of
neurological deficits arising from iron deficiency and
routinely receive supplemental iron during the neonatal
period [4].
The final 18 months of the first 1000 days (concep-
tion to 2 years of age) represent a critical window of
nutrition-dependent development, primarily in the cen-
tral nervous system [5]. Iron supports myelination,
establishment and consolidation of neurotransmitter
pathways and the substantial metabolic needs rapidly
proliferating neural networks [6]. Insufficient supply of
iron during this period has marked and well-
characterised effects on neurodevelopment [7], includ-
ing weaker cognitive, motor and social development
compared to iron-replete infants [8]. By comparison,
relatively little is known about the effects of chronic
dietary iron overexposure during this period, though
emerging concerns regarding delayed neurotoxic effects
of iron-mediated oxidative stress have sparked new de-
bate among biochemists, nutritionists and paediatri-
cians about appropriate intake during this critical
window [9–11].
Historically, most high-income countries implemented
both targeted food fortification programs, such as the
addition of inorganic iron to infant formula [12], and
broader open-market fortification of staple cereal products
[13] to address the high prevalence of iron deficiency (ID)
and iron deficiency anaemia (IDA) in both infants and the
wider populations during the mid-twentieth century. By
2011, the number of children 6–59 months meeting the
diagnostic criteria for IDA (Hb < 110 g/L [14]) in partici-
pating high-income countries had dropped to < 15% [15].
While aggressive infant formula fortification regulations
have likely contributed to this decrease—the American
Academy of Paediatrics (AAP) Committee on Nutrition
(CoN) has supported the use of formula containing 10–
12 mg/L of iron for over three decades [16]—so has in-
creased availability of complementary foods, including
iron-fortified infant cereals and staple foods [10]. The vast
majority of infants and toddlers in the USA already receive
adequate nutrient intake through diet alone [17]. In high-
income European countries, guidelines for formula fortifi-
cation are more conservative: non-breastfed term infants
are advised to consume preparations containing 4–8 mg/L
to 6 months with no set levels for 6–24-month-old chil-
dren, based on a lack of evidence supporting optimal iron
concentrations and acknowledgement of concerns regard-
ing long-term adverse outcomes arising from excessive
brain iron levels [18]. Both North American and European
guidelines are substantially more hawkish than those is-
sued by the World Health Organisation (WHO) in 2016
that encompass all countries, regardless of gross domestic
product. The WHO recommends daily oral supplementa-
tion for children aged 6–23 months with 10–12.5 mg of
elemental iron for no longer than three consecutive
months a year, and only in areas where IDA prevalence is
> 40% and malaria is not endemic [19].
By contrast, the AAP CoN also recommends augmen-
tation with direct supplementation to 12 months,
followed by the introduction of multivitamin prepara-
tions to 36 months ‘if iron needs are not being met’ [16].
Herein lies a major outstanding question: while daily
iron intake from complementary foods is substantially
more variable than regular formula consumption, does
the consumption of iron-rich foods, particularly those
containing highly bioavailable haem, compound average
intake to a point where the need for fortified formula
and/or oral supplementation becomes unnecessary? Pre-
dictive modelling of a scenario in the USA where legisla-
tion requiring open-market fortification of staple foods
is abolished suggests a modest increase in IDA preva-
lence in young children, though still well below 10%
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[20]. Screening for IDA and IDA risk (as altered haem-
atological markers indicative of ID without anaemia) is
recommended by the APP every 12 months to identify
infants in need of adjuvant supplementation [16]. We
argue that this approach has limited clinical utility, as
there is no global consensus regarding cut-off levels of
non-Hb markers used to identify ID [21]. Twelve-month
intervals between screening provide limited information
on time trends that would indicate iron stores are being
depleted, and ID itself is asymptomatic and may not be
pathological if markers remain stable over a set period.
Concerning the latter point, an interesting theory pro-
posed by Quinn [22] and supported by recent trials in
Kenya [23, 24] where bacterial gastroenteritis is endemic
posits that ID during the 6–24-month critical window is
an evolutionary mechanism intended to limit the prolif-
eration of pathogenic iron-dependent gut bacteria [22].
There is no question that adequate dietary iron intake
is critical for normal neurodevelopment and overall
healthy growth, though reassessment of long-standing
policies promoting potentially excessive intake in a high-
income setting are well overdue. A recent systematic re-
view and meta-analysis of 35 trials involving over 40,000
infants from 4 to 23 months lacked sufficient statistical
power to identify any neurodevelopmental benefit of
daily iron supplementation [25]; and the most extended
prospective cohort (n = 437; 43% attrition) assessed to
date reported that children fed ‘low’ (2.3 mg/L) iron for-
mula from 6 to 12 months outperformed those receiving
AAP CoN-comparable 12.7 mg/L fortified preparations
in all measures of neurodevelopment at 10 years, includ-
ing spatial memory, visual-motor integration and intel-
lectual ability [26]. Although far from conclusive, this
does raise some concerns about potential delayed ad-
verse long-term health outcomes beyond those charac-
terised in IDA. This systematic review and meta-analysis
will examine effects of supplementary iron intake via dir-
ect supplementation or food fortification in non-IDA in-
fants on haematological indices of iron stores, growth,
neurodevelopment and adverse health effects. This study
will help to determine if more research focussing on
iron-replete infants in contemporary high-income set-
tings are needed to inform revised nutritional guidelines.
The ultimate goal is to establish ideal intake levels that
sustain infant IDA levels at their current low rate and
minimise any potential long-term risks arising from
overexposure to iron during this critical window of
neurodevelopment.
Research questions and objective
Research questions
1. What effect does iron supplementation and/or
fortification of infant food products have on health
outcomes in iron-replete children aged 4–
24 months, compared to iron-replete children not
receiving supplemental dietary iron?
2. Do iron-replete children in upper-middle and high-
income countries show evidence of iron deficiency
(by established haematological measures) when not
receiving supplemental dietary iron?
Objective
The objective of this systematic review and meta-
analysis is to review the literature and identify all poten-
tially relevant clinical trials of iron where at least one
study arm included infants aged within the 4–24-month
window who were not classified as ID or IDA (iron-re-
plete) at trial initiation. These data will be assessed for
quality and used to examine and compare the effects of
augmented iron intake on developmental outcomes,
adverse events and haematological indices of iron status
with non-supplemented infants.
Methods
This protocol is detailed according to the recommen-
dations of the National Institute for Health and Clin-
ical Excellence (NICE; United Kingdom) [27] and the
Cochrane Handbook [28], and it is reported according
to the Preferred Reporting Items for Systematic Re-
views and Meta-Analyses Protocols (PRISMA-P) state-
ment (Supplementary Material).
Context
We will include trials conducted in any country or juris-
diction, rural and urban sites and in both community
and health care settings. We will include countries that
differ in their national policy for iron fortification,
including countries with no active policy.
Eligibility criteria
Types of studies
Crossover, individually and cluster-randomised or quasi-
randomised (provided the allocation methods are clearly
described) controlled trials will be included, as well as
follow-up studies of previous trials. We will only include
trials for which the intervention was applied directly to-
wards the child; studies attempting to improve child
health through antenatal or postnatal intervention for the
mother will not be included. Crossover studies will only
be included in the first half of the trial and analysed separ-
ately. For the primary question only (research question 1),
included randomised and quasi-randomised controlled
studies must involve a total duration of 4 weeks or longer
of supplementation or fortification. Also, non-randomised
trials—specifically individual and cluster non-randomised
controlled trials—individual and cluster-controlled before-
and-after trials, prospective cohort studies and single-arm
Hare et al. Systematic Reviews           (2019) 8:253 Page 3 of 10
studies will be included for the secondary question (re-
search question 2). Cross-sectional studies, case reports,
animal studies, editorials, letters, narrative reviews and
surveys will not be included. We will include both pub-
lished and unpublished studies.
Types of participants
Infants born at term (currently defined by the Ameri-
can College of Obstetricians and Gynaecologists as
37 weeks to 41 weeks and 6 days gestation [29]) aged
4–24 months who are classified as non-anaemic at
study commencement, per the definition of anaemia
used in each trial. While acknowledging that pre-term
infants are more susceptible to acute effects of iron
overload [1] and current practice should also be
assessed soon in terms of effective dose, near-universal
supplementation of premature and low birth weight in-
fants excludes these participants.
We will include participants fulfilling the inclusion
and exclusion criteria from all countries, settings (e.g.
rural or urban), socioeconomic status and background
malaria endemicity (iron deficiency is believed to protect
against proliferation of the Plasmodium falciparum
parasite, while conversely, malaria is a substantial con-
tributor to global anaemia burden, causing a non-iron-
related haemolytic anaemia [30]). For the secondary
question, we will examine a subset of the full dataset, in-
cluding only participants in upper-middle and high-
income countries with reported Hb concentrations.
Types of interventions
Supplemental dietary iron is defined as any source of
iron taken orally as part of a randomised controlled trial
where the amount of iron exposure is either explicitly
stated or can be established from the presented informa-
tion. Interventions to be included are direct oral supple-
mentation (drops, syrups, etc.) or fortified infant formula
or food products (milled grains, cereal products, etc.)
provided mean daily iron intake can be calculated based
on reported volume or caloric consumption data. Study
arms where mean daily iron intake cannot be obtained
or calculated will be excluded.
All non-haem iron additives will be considered, includ-
ing ferrous sulphate, ferrous fumarate, ferrous gluconate,
carbonyl iron and colloidal iron will be included.
Protein-bound iron will also be included—human breast
milk contains little inorganic iron [31], with the majority
bound to lactoferrin [32]. The frequency of supplemen-
tation or fortification will be considered for total iron in-
take but will not preclude any study from inclusion. Iron
may have been delivered as a liquid, tablet, capsule, loz-
enge or dispersible tablet.
Trials of multiple vitamins and micronutrients will be
excluded, except those that examine the additional effect
of iron with consistent levels of other vitamins and min-
erals maintained across all treatment groups. Any co-
intervention believed to influence iron uptake (e.g.
ascorbic acid, zinc, etc.) will also be included in all
groups so as the sole intervention variable between arms
is total iron intake.
Information sources
The following online databases will be searched from
inception to 30 June 2019:
 Medline via Ovid including Epub Ahead of Print, In-
Process and other non-indexed citations
 Web of Science (including Conference Proceedings
Citation Index-Science and Biosis Previews)
 Scopus
 Cochrane Central Register of Controlled Trials
(CENTRAL)
 EBSCO (Academic Search and Applied Science and
Technology databases)




Forward citation tracing will be performed during the
initial database search where available, including Med-
line, Web of Science and Scopus.
Digital theses will be searched for on:
 WorldCat
 Networked Digital Library of Theses and
Dissertations
 DART-Europe E-theses Portal
 Australasian Digital Theses Program
 Theses Canada Portal
 ProQuest-Dissertations and Theses
Only studies in English will be included, and no other
limitations will be applied to the search.
Search strategy
We will search with combinations of the following
terms:
 Iron (ferrous* ferric* trace element* micro*nutrient*)
 Supplementation (supplement* drops* liquid*)
 Fortification (fortif* formula*)
 Infants (infant* child* baby babies newborn* toddler*
pre-school* preschool*)
 Anaemia (anemia anemic anaemic)
The present draft of the search strategy to be used for
Scopus is:
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 ((TITLE-ABS-KEY(iron OR ferric* OR ferrous* OR
trace element* OR micro*nutrient*)) AND (TITLE-
ABS-KEY(infant* OR child* OR baby OR babies OR
newborn* OR neonat* OR toddler* OR preschool*
OR pre-school*)) AND (TITLE-ABS-KEY(supple-
ment* OR drops OR liquid OR fortif* OR formula*
OR diet* therap*)) AND (TITLE-ABS-KEY(anemi*
OR anaemi*)) AND (TITLE-ABS-KEY(rct OR
placebo* OR trial* OR randomi* OR cross-over OR




Full texts will be collated in the Papers desktop applica-
tion (ReadCube, USA) before entering data into Review
Manager (RevMan) v5.3 [33]. Data will be extracted or
obtained from studies using a data extraction form. The
form will be piloted on a small number of study reports
(approx. 10 eligible studies published between 2000 and
2013; based on included studies reported in Pasricha
et al. [25]) and modified if necessary.
Selection and data collection process
The selection of studies will be made by merging search
results from each database, removing any duplicates, title
assessment and examination of full-text reports according
to inclusion criteria. For studies judged to be eligible or
potentially eligible for inclusion, the full-text articles will
be sourced and assessed by two reviewers. Review authors
will extract data from eligible reports using the form. One
author will enter data into RevMan, and the second
author will carry out checks for accuracy. We will resolve
any discrepancies through discussion or consult a third
author. Any discrepancies in the classification that arise
during this process will be resolved by consensus between
the two reviewers and a third reviewer. For studies that
progress to the full-text screening stage, we will record the
reason that studies were excluded.
If there are cases where it is unclear whether the inclu-
sion criterion is met, we will attempt to contact the
study corresponding author for clarification; if no
response is received within 4 weeks of the request, or
the requested information is not provided, the informa-
tion within the full-text article will be used to decide on
the eligibility of the study.
A diagram will be created to report the flow of studies
through the systematic review.
Data items
For each study, we will collect data on source, study
authors and contact information, design, setting, partici-
pants, the interventions applied, reported comorbidities
outcomes measured, a full description of the results
including the stated outcomes listed above, national
policies on iron fortification in place at the time of the
study, funding sources and other relevant outcomes
identified using the standardised collection form. We
will attempt to find relevant missing information by
contacting the primary/corresponding author of the
study. Extracted data will be summarised in tables. If any
data extraction discrepancies arise, these will be resolved
by discussion and consensus among the review team.
Outcomes and prioritisation
Primary outcomes
We will examine the effect of supplemental dietary iron
on health outcomes associated with IDA in infancy.
These include:
1. Measures of physical growth, including weight (kg),
weight-for-age (Z-score), length (cm), length-for-
age (Z-score), weight-for-length (Z-score), stunting
and wasting.
2. Neurodevelopmental indices, where available,
including (but not limited to) scores on validated
developmental tests for example Bayley scales, pre-
school language scale, child behaviour checklist,
Denver developmental screening test, Fagan test of
infant intelligence, Infant behaviour questionnaire,
toddler behaviour questionnaire, cognitive tasks and
motor testing, infant attachment/bonding and phys-
ical activity/attentiveness (as measured by trialists).
3. Anaemia (defined as the Hb concentration cut-off
used in the study, adjusted by altitude and age as
appropriate) and haematological iron indices,
including blood Hb concentration (g/L), ferritin
(FTN) concentration (ng/mL), transferrin (Tf)
concentration (mg/mL) and saturation (Tfsat; %),
soluble transferrin receptor (TfR; mg/mL) and the
zinc protoporphyrin (ZPP) to haem ratio. Note that
study-specific Hb concentrations for IDA diagnosis
are used in place of the < 110 g/L level set by the
WHO and most commonly used in clinical practice
[14] to include trials where lower Hb cut-offs were
used. This is justified on the basis of preliminary
reports of asymptomatic infants with sub-110 g/L
Hb levels that clinically identify them as IDA [34]
and calls for a re-evaluation of current diagnostic
criteria for infants [18].
4. Safety and adverse health effects (including
vomiting, fever, diarrhoea [both prevalence and
incidence], infectious disease, constipation,
hospitalisation or non-regular clinic visits, morbidity
from iron-related poisoning and mortality).
5. Other micronutrient intake and status where an
effect from iron is suspected (calcium, zinc,
vitamin A, etc.).
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Secondary outcomes
To examine the effects of iron supplementation and/or
food fortification on clinical markers of IDA, we will
report:
6. Changes from baseline in haematological iron
indices, including blood Hb concentration (g/L),
FTN concentration (ng/mL), Tf concentration (mg/
mL) and Tfsat (%), and soluble TfR.
Data will be extracted from trials with a study arm
meeting the inclusion criteria that were performed in
upper-middle and high-income countries. Classification
of economies is based on that used by the World Bank
for the 2018/19 fiscal year [35].
Timing of outcome assessment will be based on the
duration of the intervention and trial follow-up after
completion of the intervention period. We will perform
a subgroup analysis where studies are segregated by the
duration of the intervention and outcomes defined as
the difference between trial completion and commence-
ment, compared against trial length (rate of change). We
will also examine measured outcomes following trial
completion (e.g. those measured up to 6 months follow-
ing completion of the trial, those measured 6–12 months
following completion of the trial and those measured
more than a year following completion of the trial).
Risk of bias in individual studies
Statistical analyses will be undertaken using RevMan and
Stata Statistical Software v15.1 (StataCorp, USA) [36].
Risk of bias will be assessed by two review authors inde-
pendently. We will resolve any discrepancies through dis-
cussion or consult a third author to resolve discrepancies.
For the included randomised controlled trials, risk of
bias will be assessed using the RoB 2.0 tool [37], specific
for the type of trial (individually randomised parallel
group trial, cluster-randomised parallel group trial, indi-
vidually randomised cross-over trial) and each bias do-
main will be assessed for each outcome within each
included study. The following domains will be classified:
1. Bias arising from the randomisation process
2. Bias due to deviations from intended interventions
3. Bias due to missing outcome data
4. Bias in measurement of the outcome
5. Bias in the selection of the reported result
For cluster-randomised parallel group trials only, we
will assess an additional domain:
6. Bias arising from the timing of identification and
recruitment of individual participants with the
timing of randomisation
Risk of bias in each domain will be classified as
low, high or some concerns. We will reach an overall
risk of bias judgement as low, high or some concern
for each outcome within each included study across
all domains according to the process outlined for RoB
2.0 [37].
For the included quasi-randomised and non-
randomised studies, risk of bias will be assessed using the
Risk Of Bias In Non-randomised Studies-of Interventions
tool (ROBINS-I) [38] and each bias domain will be
assessed for each outcome within each included study.
The following domains will be classified:
1. Bias due to confounding
2. Bias due to the selection of participants into the
study
3. Bias in the classification of interventions
4. Bias due to deviations from intended interventions
5. Bias due to missing data
6. Bias in measurement of outcomes
7. Bias in the selection of the reported result
Risk of bias in each domain will be classified as low,
moderate, severe, critical or no information. We will
reach an overall risk of bias judgement as low, moderate,
severe, critical or no information for each outcome
within each included study across all domains according
to the process outlined for ROBINS-I [38].
For the included single-arm studies, bias will be
assessed using a modified ROBINS-I approach [38] de-
scribed by Jullien et al. [39]; and the Quality in Progno-
sis Studies tool [40] and checklist used by NICE [27]
with the following domains:
1. The study sample represents the population of
interest concerning key characteristics, sufficient to
limit potential bias to the results.
2. Loss to follow-up is unrelated to key characteristics
(that is, the study data adequately represent the
sample), sufficient to limit potential bias.
3. The prognostic factor of interest is adequately
measured in study participants, sufficient to limit
potential bias.
4. The outcome of interest is adequately measured in
study participants, sufficient to limit bias.
5. Important potential confounders are appropriately
accounted for, limiting potential bias for the
prognostic factor of interest.
6. The statistical analysis is appropriate for the design
of the study, limiting the potential for the
presentation of invalid results.
If a standardised tool for single-arm studies was to be
released during the conduct of our systematic review, we
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will adopt this tool and conduct the risk of bias assess-
ment for single-arm studies accordingly.
Data synthesis and analysis
Criteria for quantitative synthesis of data
If the outcome is reported for more than one trial, we
plan to conduct meta-analysis but will report only if no
substantial statistical heterogeneity is detected. We will
quantify heterogeneity using the I2 test; substantial
heterogeneity is considered when I2 exceeds 50%.
Summary measures, data handling and methods for
combining data
For continuous outcomes, we will use mean differences
(MD) with 95% confidence intervals (CIs) if outcomes
were measured in the same way or standardised mean
differences (SMD) and 95% CIs if different scales were
applied across studies to measure the same outcome.
For binary outcomes, we will use the risk ratio (RR) (pri-
mary outcomes) or proportion (secondary outcomes)
and 95% CIs.
Unit of analysis
We will use the participant as the unit of analysis. For
cluster or cross-over randomised controlled trials, we
will take the level of randomisation into account for
cluster trials and use only data of the first treatment
period for cross-over trials. In the case of multi-arm tri-
als, we will combine relevant groups to create two arms
to allow for single-pair comparisons. For continuous
outcomes, the feasibility hereof depends on the availabil-
ity of the sample size, mean and standard deviation
within each arm.
Missing data
We will contact the primary/corresponding authors of
the studies in case of missing (summary) data that we
cannot derive from the available data or in case of insuf-
ficient methodological detail. We will record the attri-
tion (e.g. lost to follow-up, drop-out, withdrawal of
consent) for included studies and review the method-
ology used by the authors to assess the adequacy in deal-
ing with missing data. We will perform an available case
analysis (includes only those participants whose outcome
data are known) and imputed case analysis (with missing
values imputed using specific assumptions).
Assessment of heterogeneity
We anticipate that there may be heterogeneity between
studies attributable to methodological (i.e. formulations,
implementation/ delivery strategies), study type (rando-
mised/quasi-randomised), population (baseline Hb and
iron status, setting) and implementation differences, as
well as statistical heterogeneity. Clinical heterogeneity
will be explored via the characteristics of the included
studies. Statistical heterogeneity will be examined visu-
ally using forest plots and statistically using the
Cochran’s Q test, the I2 statistic and tau2.
Subgroup analyses
We plan several subgroup analyses for the primary
question:
1. By gross national income per capita (by World
Bank criteria) of the country in which trial was
performed: high-income, upper-middle income, or
other.
2. By national food fortification policy: mandatory iron
fortification, voluntary iron fortification, no iron
fortification.
3. By baseline iron stores (by serum ferritin
concentration according to WHO guidelines for
children < 5 years): sufficient (≥ 12 μg/L),
insufficient (< 12 g/L) or not reported.
4. By baseline Hb (by WHO guidelines): non-anaemic
(≥ 110 g/L), mild anaemia (100–109 g/L), moderate
anaemia (70–99 g/L), severe anaemia (< 70 g/L) or
not reported.
5. By route of administration: direct supplement,
fortified food.
6. By mean dose of iron supplementation per day:
12.5 mg or less, > 12.5 mg–< 3 mg, 31–59 mg,
60 mg or higher.
7. By duration of iron supplementation: 1–3 months,
greater than 3 months.
8. By duration of follow-up: < 6 months, 6–12 months,
greater than 12 months.
9. By breastfeeding status: breastfeeding, weaned, not
reported.
10. By sex of the participants: male, female, not
reported
11. By regional malaria endemicity [41], where PfPR =
Plasmodium falciparum parasite rate, and PfAPI =
P. falciparum annual parasite incidence (intense
stable endemic [PfPR ≥ 40%], moderate stable
endemic [PfPR 5.1–33.99%], unstable endemic
[PfPR ≤ 5%, PfAPI = 0.01–0.1%], non-endemic
[PfAPI < 0.01%]).
We will explore the Forest plots visually and use statis-
tical tests to investigate subgroup differences formally.
Sensitivity analysis
We plan a number of sensitivity analyses to investigate the
robustness of results to decisions and assumptions on:
1. Studies without premature or low birth weight
participants
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2. Studies with inactive comparator arm only
3. Studies with low risk of bias only
4. Studies that were randomised only
5. Studies that were single-arm only (secondary
objective only)
6. Assumptions made on cluster-randomised
controlled trials (e.g. intra-cluster correlation)
7. Assumptions made on missing data imputation
Quantitative synthesis
We will analyse the data with both fixed-effect and
random-effects models and will present the results of
the random-effects meta-analysis. If the results of both
models differ, only then will we also report the fixed-
effect meta-analysis.
For the primary question, the meta-analysis will
provide an overall estimate of the effect of iron supple-
mentation or fortification compared to no intervention/
placebo for outcomes based on comparative data only.
For the secondary question, it will provide an estimate
of the outcomes based on data from comparative (separ-
ate arms) and non-comparative (single-arm) trials.
Meta-bias(es)
We anticipate that studies in infants may have small
sample sizes and be less likely to produce significant
findings, which might have resulted in publication bias
or time-lag bias. Possible reporting bias of included stud-
ies will be assessed using funnel plots if ten or more
studies are included in a particular analysis. Statistical
testing will be performed for funnel plot asymmetry.
Confidence in cumulative evidence
If appropriate, we will present a ‘Summary of Findings’
table for the quantitative outcomes. In this case, the
quality and strength of the body of evidence will be
assessed based on the Grading of Recommendations
Assessment, Development and Evaluation (GRADE)
method [42].
Discussion
It has widely been assumed that moderately excessive
dietary iron intake during development has no acute or
chronic adverse health effects, aside from conflicting
reports of mild gastrointestinal symptoms. However, the
long-term health effects, particularly regarding neurode-
velopment, remain unclear. The WHO has identified
that the collection of ‘additional data on the safety of
iron supplementation in non-anaemic or non-iron-
deficient children’ should be a research priority, and that
‘additional long-term studies on functional outcomes
(e.g. cognitive and motor development)’ should be con-
ducted [19]. For a child to be considered iron-replete or
non-ID/IDA, the most widely used clinical definition is
blood Hb levels > 110 g/L. However, other haemato-
logical indices, including transferrin saturation and
ferritin levels, can also provide a complete picture of
iron status.
The strategy to meet our primary objective has been
designed to compare the effect of iron supplementation
or fortification of infant food products to no interven-
tion/placebo on health outcomes in iron-replete children
aged 4–24 months. To address the WHO’s identified
research priorities, the effects of iron supplementation
and/or fortification on (i) weight and growth, (ii) neuro-
developmental outcomes and (iii) haematological indices
of iron status in children who are considered iron-
replete (Hb > 110 g/L) will be collected via this system-
atic review and, if possible, undergo meta-analysis.
We have also designed our secondary objective to
determine if iron-replete children in upper-middle and
high-income countries who receive no supplemental
dietary iron show evidence of a change in Hb concentra-
tion over time by established measures. With growing
concern about delayed effects of unnecessary iron intake
during critical windows of development, we believe this
study is timely and will provide an evidence-based case
for revisiting nutritional guidelines in these countries,
some of which are based on public health policies that
were initially devised over half a century ago.
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